深圳市海普瑞药业集团股份有限公司 is a multinational pharmaceutical company focused on providing high-quality, safe, and effective medications and services to patients around the world, driven by unmet clinical needs.

深圳市海普瑞药业集团股份有限公司

Hepalink Group | 556 followers on LinkedIn. Discover, develop, and commercialize high-quality, safe and effective medicines and services to address patients’ unmet  | Established in 1998 in Shenzhen, China, Hepalink is a leading multinational biopharmaceutical company dual-listed in Hong Kong and mainland China, with its core business in heparin industrial chain, large molecule biologics CDMO services, and the research, development, and commercialization of innovative drugs.

These three synergistic business segments are driven by the mission of addressing patients’ unmet medical needs and bringing safe and effective therapies and services to patients around the world.

Heparin Supply Chain / Global Supply Chain Division at Shenzhen Hepalink Pharmaceutical Co., Ltd.

Danuta (Danka) Andersen

Sr Manager , Investment analyst at Shenzhen Hepalink Pharmaceutical Co., Ltd.

Frances Huangmin

Director of Internal Audit and internal control at Shenzhen Hepalink Pharmaceutical Co., Ltd.

Andy Wu

Intelligence Investigator and Assessor

Bei Liu

Hepalink Group

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through four segments: Finished dose pharmaceutical products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others. Its pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium API and enoxaparin sodium API; and other products, such as pancreatin API. The company is also involved in the provision of research and development, manufacturing, quality management, and program management services; and development and manufacture of recombinant pharmaceutical products, critical non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical products. In addition, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; research, development, and production of biopharmaceuticals; production and sale of heparin sodium; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 17, 2024 8:45 PM	37065b29
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 17, 2024 8:45 PM	8347b9a3
crunchbase trigger	general	Nov 17, 2024 8:45 PM	90bb29cf
crunchbase profile	general	Nov 17, 2024 9:05 PM	915b7b83
li profile	general	Nov 17, 2024 8:45 PM	60d24037
translate crunchbase fundingrounds	general
peers	general	Nov 17, 2024 8:45 PM	9168003b
news basic	general	Nov 17, 2024 8:45 PM	33924754
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

0023

COM:HEPALINK

深圳市海普瑞药业集团股份有限公司

Last Close

11.38

22/11 07:04

Market Cap

11.43B

Beta: -

Volume Today

4.27M

Avg: -